Opendata, web and dolomites

ZIKAVAX SIGNED

Fast track development of a Zika vaccine based on measles vector

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ZIKAVAX project word cloud

Explore the words cloud of the ZIKAVAX project. It provides you a very rough idea of what is the project "ZIKAVAX" about.

manufacturing    borns    consequently    treatments    human    declared    flavivirus    proof    expression    bioscience    severe    neurological    affordable    candidate    purity    isolated    track    health    standard    humans    congenital    zikavax    preclinical    infection    volunteers    committed    energie    disease    previously    complications    give    demonstrated    spread    preventive    safe    organization    commissariat    therapies    record    nor    institut    variety    issue    demonstration    public    malformations    date    mosquito    innovative    adaptability    mice    platform    ia    outbreak    agrave    safety    atomique    ultimate    world    rapid    measles    vaccines    antigen    primates    1947    model    unaffected    regions    effectiveness    pathogens    recombinant    emergency    vaccine    virus    borne    adult    epidemiological    brain    vector    urgent    infectious    adults    clinical    zika    immunogenicity    truly    immunisation    yield    trial    themis    pasteur    diseases   

Project "ZIKAVAX" data sheet

The following table provides information about the project.

Coordinator
EUROPEAN VACCINE INITIATIVE EWIV 

Organization address
address: VOSSSTRASSE 2 GEB 4040
city: HEIDELBERG
postcode: 69115
website: http://www.euvaccine.eu/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.zikavax.eu
 Total cost 4˙918˙137 €
 EC max contribution 4˙918˙137 € (100%)
 Programme 1. H2020-EU.3.1.2. (Preventing disease)
 Code Call H2020-SC1-2016-RTD
 Funding Scheme RIA
 Starting year 2016
 Duration (year-month-day) from 2016-10-01   to  2020-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EUROPEAN VACCINE INITIATIVE EWIV DE (HEIDELBERG) coordinator 673˙968.00
2    THEMIS BIOSCIENCE GMBH AT (WIEN) participant 3˙192˙862.00
3    INSTITUT PASTEUR FR (PARIS CEDEX 15) participant 562˙290.00
4    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR (PARIS 15) participant 489˙016.00

Map

 Project objective

Zika virus is an emerging mosquito-borne flavivirus. Although already isolated in 1947, to date there are no specific treatments nor any vaccines available against Zika virus disease, making it a truly neglected infectious disease. The recent rapid spread of the Zika virus in previously unaffected regions has provided strong epidemiological evidence that infection with this virus might be associated with neurological complications in adults and with an increase in severe congenital brain malformations of new-borns. Consequently, the World Health Organization has declared the recent outbreak of the Zika virus a public health emergency. The ZIKAVAX proposal has the objective to address this urgent public health issue by promoting the rapid development of a safe, effective, and affordable preventive vaccine against Zika virus infection. To achieve this goal, ZIKAVAX will use a delivery platform technology based on a measles vaccine vector with demonstrated proof of principle in humans and a preclinical track record of rapid adaptability and effectiveness for a variety of pathogens. The manufacturing process for these measles vector-based vaccines has been developed to give high yield and purity using standard equipment. In ZIKAVAX, following antigen selection and expression, immunisation studies will be conducted with the Zika vaccine candidate in mice and in a challenge model in non-human primates that will developed by the consortium. The ultimate goal of ZIKAVAX is the demonstration of safety and immunogenicity of a recombinant measles-Zika vaccine candidate in adult volunteers in a phase Ia clinical trial. ZIKAVAX is driven by a strongly committed and effective consortium of four leading European organisations highly experienced in vaccine research and development. Its partners include the European Vaccine Initiative, Institut Pasteur, Themis Bioscience GmbH and the Institute of Emerging Diseases and Innovative Therapies from the Commissariat à l’Energie Atomique.

 Deliverables

List of deliverables.
Launch of the website Websites, patent fillings, videos etc. 2019-05-30 15:16:10

Take a look to the deliverables list in detail:  detailed list of ZIKAVAX deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ZIKAVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ZIKAVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.2.)

RISCC (2020)

RISK-BASED SCREENING FOR CERVICAL CANCER

Read More  

EMPOWER (2020)

European platforM to PromOte Wellbeing and HEalth in the woRkplace

Read More  

EXIMIOUS (2020)

Mapping Exposure-Induced Immune Effects: Connecting the Exposome and the Immunome

Read More